

## **CURRENT REPORT 32/2023**

**June 14<sup>th</sup>, 2023**

### **Appointment of new Members of the Supervisory Board of Ryvu Therapeutics S.A.**

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Company") informs that on June 14<sup>th</sup>, 2023 the Ordinary General Meeting of the Company adopted resolutions, pursuant to which Dr. Scott Z. Fields and Dr. Peter Smith were appointed to the Supervisory Board of the Company as of the same date.

Below the Company provides information on the educational background, qualifications and positions previously held by Dr. Scott Z. Fields.

Dr. Scott Z. Fields is a medical oncologist/hematologist with more than 30 years of experience in clinical drug development. Dr. Fields currently serves as Chief Medical Officer at NeoTX Therapeutics.

Prior to joining NeoTX, Dr. Fields was the Global Head of Development for Oncology at Bayer Pharmaceuticals. In this role, he was responsible for early and late-stage development, including several novel oncology medicines across the platforms for targeted therapies/precision medicine, antibody-drug/alpha radiation conjugates and novel Immuno-Oncology agents, such as Darolutamide (Androgen Receptor inhibitor for prostate cancer), Larotrectinb (NTRK inhibitor - tissue agnostic), Xofigo (Radium223 – alpha particle emitter for prostate cancer), Copanlisib (PI3K inhibitor for lymphoma) and Regorafenib (multi-kinase inhibitor for liver, colon and GIST). Prior to his position at Bayer, Dr. Fields held senior positions at Vertex Pharmaceuticals, SmithKline Beecham, Amgen, Eisai, and Arno Therapeutics and helped bring over a dozen drugs to market. He also practiced oncology/hematology and transplant medicine in academic settings.

Dr. Fields received his medical degree from SUNY Downstate Medical Center in New York, followed by training in internal medicine and hematology, and oncology at Columbia University Medical Center.

Dr. Scott Z. Fields is not listed in the Registry of Insolvent Debtors maintained on the basis of the National Court Registry act, does not engage in competition with Ryvu Therapeutics S.A, is not a partner in civil law partnerships or limited companies which engage in such competition and is not a member of any official bodies of other legal entities which engage in such competition. Dr. Scott Z. Fields is not listed in the Register of Insolvent Debtors maintained on the basis of the National Court Register Act.

Below the Company provides information on the educational background, qualifications and positions previously held by Dr. Peter Smith.

Dr. Peter Smith is a pharmaceutical executive with over 20 years of experience in drug discovery and development. He has proven experience in company building and the discovery and development of new therapeutics for various diseases of unmet need. Dr. Smith is Co-Founder and currently Chief Executive Officer of Remix Therapeutics. He also serves as Entrepreneur-In-Residence at Atlas Venture, where he is Co-founder and Acting CSO of Amplify Medicine, as well as an advisor to other Atlas portfolio companies.

Previously, he served as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine, he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development.

Dr. Smith received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.

Dr. Peter Smith is not listed in the Registry of Insolvent Debtors maintained on the basis of the National Court Registry act, does not engage in competition with Ryvu Therapeutics S.A, is not a partner in civil law partnerships or limited companies which engage in such competition and is not a member of any official bodies of other legal entities which engage in such competition. Dr. Peter Smith is not listed in the Register of Insolvent Debtors maintained on the basis of the National Court Register Act.

Disclaimer: This English language translation has been prepared solely for the convenience of English speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

**Legal basis:** Article 56.1.2 of the Act on Offerings

**Representatives of the Issuer:**

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board